Carisma Therapeutics Shares Soar Over 130% on Groundbreaking Moderna Collaboration for In Vivo CAR-M Therapies
Breakthrough Hope for HCM Patients: Cytokinetics Unveils Promising Aficamten Data at European Cardiology Congress
Cytokinetics Unveils Groundbreaking MAPLE-HCM Results for Aficamten at ESC Congress
Amgen may be evaluating Cytokinetics bid; CYTK wants $130 $145 a share report
Novartis said to have backed away from a deal for Cytokinetics